Praxis Precision Medicines, Inc.
PRAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689548
No open-market purchases or sales by Praxis Precision Medicines, Inc. insiders were filed in the last 90 days; 309 institutions reported holding it in 13F filings for Q2 2026, worth $11.3B in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Praxis Precision Medicines, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +3 vs. Q1 2024
- Shares held
- 18.4M
- +2.51M (+15.7%) vs. Q1 2024
- Total value
- $762.1M
- −$209.2M (−21.5%) vs. Q1 2024
- New holders
- 38
- 43 more added
- Sold out
- 35
- 25 more reduced
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PRAX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 309 | $11.3B |
| Q1 2026 | 291 | $10.2B |
| Q4 2025 | 250 | $8.69B |
| Q3 2025 | 152 | $1.31B |
| Q2 2025 | 144 | $1.02B |
| Q1 2025 | 150 | $889.3M |
| Q4 2024 | 162 | $1.67B |
| Q3 2024 | 134 | $1.09B |
| Q2 2024 | 113 | $762.1M |
| Q1 2024 | 111 | $971.3M |
| Q4 2023 | 60 | $178.6M |
| Q3 2023 | 74 | $195.6M |
| Q2 2023 | 78 | $134.6M |
| Q1 2023 | 87 | $43.1M |
| Q4 2022 | 104 | $108.1M |
| Q3 2022 | 108 | $95.7M |
| Q2 2022 | 95 | $105.5M |
| Q1 2022 | 103 | $463.4M |
| Q4 2021 | 100 | $863.1M |
| Q3 2021 | 93 | $791.5M |
| Q2 2021 | 80 | $751.0M |
| Q1 2021 | 68 | $1.19B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Praxis Precision Medicines, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| PFM Health Sciences, LP | 453,146 | $18.7M | 1.02% | −24,459−5.1% | Reduced |
| Soleus Capital Management, L.P. | 533,015 | $22.0M | 1.94% | +495,747+1,330.2% | Added |
| Cormorant Asset Management, LP | 685,000 | $28.3M | 1.65% | −625,000−47.7% | Reduced |
| VR Adviser, LLC | 706,131 | $29.2M | 1.86% | +50.0% | Added |
| Verition Fund Management LLC | 748,320 | $31.0M | 0.24% | +202,912+37.2% | Added |
| Perceptive Advisors LLC | 750,230 | $31.0M | 0.75% | −71,359−8.7% | Reduced |
| State Street Corp | 819,142 | $33.9M | 0.00% | +774,634+1,740.4% | Added |
| Price T Rowe Associates Inc | 938,579 | $38.8M | 0.00% | +402,580+75.1% | Added |
| Vanguard Group Inc | 977,145 | $40.4M | 0.00% | +233,076+31.3% | Added |
| Point72 Asset Management, L.P. | 1,051,701 | $43.5M | 0.14% | +97,561+10.2% | Added |
| Adage Capital Partners GP, L.L.C. | 1,134,083 | $46.9M | 0.09% | −258,945−18.6% | Reduced |
| Ra Capital Management, L.P. | 1,235,599 | $51.1M | 0.68% | +407,219+49.2% | Added |
| BlackRock Inc. | 1,294,000 | $53.5M | 0.00% | +1,072,255+483.6% | Added |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −460,512−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −225,000−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −168,388−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −106,159−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −94,332−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −93,000−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −82,254−100.0% | Sold out |
| Altium Capital Management LP | 0 | $0 | 0.00% | −78,100−100.0% | Sold out |
| Farallon Capital Management, L.L.C. | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Superstring Capital Management LP | 0 | $0 | 0.00% | −40,119−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −34,867−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −27,263−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −21,152−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −16,180−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −14,764−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −13,522−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −13,311−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −12,336−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −11,776−100.0% | Sold out |
| Marathon Trading Investment Management LLC | 0 | $0 | 0.00% | −9,000−100.0% | Sold out |
| American Century Companies Inc | 0 | $0 | 0.00% | −7,612−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −5,627−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −4,261−100.0% | Sold out |
| Boulder Hill Capital Management LP | 0 | $0 | 0.00% | −4,200−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −4,028−100.0% | Sold out |
| Coastal Bridge Advisors, LLC | 0 | $0 | 0.00% | −3,846−100.0% | Sold out |
| Chase Investment Counsel Corp | 0 | $0 | 0.00% | −3,768−100.0% | Sold out |
| Polymer Capital Management (HK) LTD | 0 | $0 | 0.00% | −3,726−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −2,465−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −109−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −966−100.0% | Sold out |
| FSA Wealth Management LLC | – | – | – | – | Not filed |